Denmark rationalised cheaper diabetic medicines and restricted GLP-1 analogues. The so-called GLP-1 analogues, which include is known under the product names Ozempic, Trulicity, Rybelsus and Victoza, is significantly more expensive than other types of diabetes medication (so-called DPP-4 inhibitors, SGLT-2 inhibitors, beta-cell stimulants and metformin)